Voices From TCT 2015: FDA's Bram Zuckerman On Benefit-Risk Assessments And Approaching FDA Early
This article was originally published in The Gray Sheet
Executive Summary
“The Gray Sheet” talks to FDA cardiovascular device review lead Bram Zuckerman about his decades-long experience at the agency, the future of cardiac devices and why some companies are hesitant about talking to FDA early on about their product development in this podcast interview from the Transcatheter Cardiovascular Therapeutics meeting in San Francisco.